MA27630A1 - Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifs - Google Patents
Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifsInfo
- Publication number
- MA27630A1 MA27630A1 MA28483A MA28483A MA27630A1 MA 27630 A1 MA27630 A1 MA 27630A1 MA 28483 A MA28483 A MA 28483A MA 28483 A MA28483 A MA 28483A MA 27630 A1 MA27630 A1 MA 27630A1
- Authority
- MA
- Morocco
- Prior art keywords
- combination
- agonist
- active ingredients
- powerful
- medicine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention a trait à l'utilisation d'un bronchodilateur en combinaison avec un ou plusieurs autres principes actifs pour le traitement de troubles respiratoires et notamment l'asthme et la broncho-pneumopathie chronique obstructive (BPCO), et aux compositions pharmaceutiques contenant lesdits principes actifs. En particulier, l'invention a trait à l'utilisation d'un agoniste (beta)2 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-méthoxyphényl)-1méthyléthyl]amino]éthyl-2(1H)-quinolinone et/ou des sels et/ou des solvates physiologiquement acceptables de celui-ci en tant que bronchodilateur en combinaison avec d'autres principes actifs.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03004184A EP1452179A1 (fr) | 2003-02-27 | 2003-02-27 | Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid |
Publications (1)
Publication Number | Publication Date |
---|---|
MA27630A1 true MA27630A1 (fr) | 2005-11-01 |
Family
ID=32748803
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28483A MA27630A1 (fr) | 2003-02-27 | 2005-09-06 | Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifs |
Country Status (32)
Country | Link |
---|---|
US (1) | US20070020190A1 (fr) |
EP (3) | EP1452179A1 (fr) |
JP (1) | JP2006519204A (fr) |
KR (1) | KR20050104367A (fr) |
CN (2) | CN100370986C (fr) |
AR (1) | AR043419A1 (fr) |
AT (1) | ATE401887T1 (fr) |
AU (1) | AU2004216472B2 (fr) |
BR (1) | BRPI0408047A (fr) |
CA (1) | CA2517321A1 (fr) |
CY (1) | CY1108360T1 (fr) |
DE (1) | DE602004015260D1 (fr) |
DK (1) | DK1603565T3 (fr) |
EA (1) | EA008828B1 (fr) |
ES (1) | ES2309503T3 (fr) |
HK (1) | HK1087009A1 (fr) |
HR (1) | HRP20050726A2 (fr) |
MA (1) | MA27630A1 (fr) |
ME (1) | MEP32208A (fr) |
MX (1) | MXPA05009007A (fr) |
NO (1) | NO20053959L (fr) |
NZ (1) | NZ541997A (fr) |
PE (1) | PE20050290A1 (fr) |
PL (1) | PL377814A1 (fr) |
PT (1) | PT1603565E (fr) |
RS (1) | RS20050615A (fr) |
SA (1) | SA04250122B1 (fr) |
SI (1) | SI1603565T1 (fr) |
TN (1) | TNSN05186A1 (fr) |
UA (1) | UA82217C2 (fr) |
WO (1) | WO2004075896A1 (fr) |
ZA (1) | ZA200506820B (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US20060257324A1 (en) * | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
EP1651224B1 (fr) * | 2003-07-31 | 2011-10-05 | Boehringer Ingelheim International GmbH | Medicaments pour inhalation comportant un agent a activite anticholinergique et un betamimetique |
EP1654001A2 (fr) * | 2003-08-05 | 2006-05-10 | Boehringer Ingelheim International GmbH | Medicament pour inhalation comprenant des steroides et un betamimetique |
EP1670482B2 (fr) | 2003-09-16 | 2022-06-29 | Covis Pharma B.V. | Utilisation de ciclesonide dans le traitement de maladies respiratoires |
AU2006224842B2 (en) * | 2005-03-16 | 2011-09-29 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
EP2484382A1 (fr) * | 2005-03-30 | 2012-08-08 | Schering Corporation | Médicament à base d'un inhibiteur de la phosphodiestérase IV sous une forme adaptée à l'inhalation |
DE602006010088D1 (de) * | 2005-08-01 | 2009-12-10 | Chiesi Farma Spa | Pharmazeutische formulierungen mit einem langzeit-beta-2-agonisten zur verabreichung durch verneblung |
CA2627982C (fr) | 2005-11-10 | 2013-09-10 | Nicholas S. Bodor | Esters anticholinergiques moderes |
AU2006329042B2 (en) * | 2005-12-21 | 2012-02-02 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-agonists, PDE4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
JP2010526763A (ja) * | 2006-05-24 | 2010-08-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系疾患を治療するための新規な長時間作用型の薬剤組成物 |
EP1953143A1 (fr) * | 2007-01-30 | 2008-08-06 | CHIESI FARMACEUTICI S.p.A. | Processus de préparation de monohydrochloride de 8-hydroxy-5-[(1R)-1-hydroxy-2[[(1R)-2-(4-méthoxyphényl)-1-méthyléthyl]amino]éthyl]-2(1H)-quinolinone |
EP2124915A2 (fr) * | 2007-02-19 | 2009-12-02 | Cipla Limited | Combinaisons pharmaceutiques |
WO2009079078A1 (fr) | 2007-12-14 | 2009-06-25 | Labogroup S.A.S. | Administration de produits alimentaires sous forme d'aérosols |
EP2100599A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
EP2100598A1 (fr) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Composition à inhaler comprenant aclidinium pour le traitement de l'asthme et de maladies respiratoires obstructives chroniques |
WO2010013240A1 (fr) | 2008-07-31 | 2010-02-04 | Dekel Pharmaceuticals Ltd. | Compositions et procédés de traitement de troubles inflammatoires |
WO2010097188A1 (fr) * | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Particules pour inhalation comprenant un sel de carmotérol et un corticostéroïde |
CN102448498A (zh) * | 2009-05-25 | 2012-05-09 | 奇斯药制品公司 | 包括肺表面活性物质和类固醇的治疗组合 |
ES2774391T3 (es) | 2009-05-29 | 2020-07-20 | Pearl Therapeutics Inc | Composiciones, métodos y sistemas para la administración respiratoria de dos o más agentes activos |
AU2015201037C1 (en) * | 2009-05-29 | 2017-07-27 | Pearl Therapeutics, Inc. | Respiratory delivery of active agents |
WO2011136753A1 (fr) * | 2010-04-26 | 2011-11-03 | Mahmut Bilgic | Combinaison de carmotérol et de fluticasone utilisée pour le traitement de maladies respiratoires |
CN102247597B (zh) * | 2010-05-19 | 2015-01-07 | 天津金耀集团有限公司 | 一种糖皮质激素与支气管扩张剂的吸入剂 |
US20130274232A1 (en) | 2010-07-16 | 2013-10-17 | Cipla Limited | Pharmaceutical Compositions |
WO2012010854A1 (fr) | 2010-07-23 | 2012-01-26 | Cipla Limited | Composition pharmaceutique |
CN102416179B (zh) * | 2010-09-28 | 2014-05-07 | 益得生物科技股份有限公司 | 用于哮喘的吸入性复方组合物 |
TWI399202B (zh) * | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
EP2510928A1 (fr) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium pour l'amélioration du sommeil des patients avec des maldadies respiratoires |
JP6560986B2 (ja) * | 2013-03-15 | 2019-08-14 | ヴェローナ ファーマ ピーエルシー | 複合製剤 |
WO2016044370A1 (fr) | 2014-09-16 | 2016-03-24 | India Globalization Capital, Inc. | Composition cannabinoïde et méthode de traitement de la douleur |
EP3223807B1 (fr) * | 2014-11-24 | 2021-09-15 | The Board of Trustees of the University of Illinois | Méthode de prévention ou de traitement d'une maladie ou d'une affection pulmonaire |
CA2974895A1 (fr) | 2015-01-25 | 2016-07-28 | India Globalization Capital, Inc. | Compositions et procedes de traitement de troubles epileptiques |
US10596159B2 (en) | 2015-08-12 | 2020-03-24 | India Globalization Capital, Inc. | Method and composition for treating cachexia and eating disorders |
EP3471746A4 (fr) | 2016-06-15 | 2020-02-26 | India Globalization Capital, Inc. | Méthode et composition pour traiter des troubles epileptiques |
CN115337311B (zh) * | 2022-09-26 | 2023-05-09 | 南京恒道医药科技股份有限公司 | 一种治疗呼吸系统疾病的组合物及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
CN100548277C (zh) * | 1997-03-20 | 2009-10-14 | 先灵公司 | 粉末附聚物的制备方法 |
IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
US20020081266A1 (en) * | 1999-08-20 | 2002-06-27 | Norton Healthcare Ltd. | Spray dried powders for pulmonary or nasal administration |
PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
JP5392880B2 (ja) * | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
EP1340492A1 (fr) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique |
KR100947409B1 (ko) * | 2002-03-01 | 2010-03-12 | 키에시 파르마슈티시 엣스. 피. 에이. | 포모테롤 초미세 조성물 |
EP1595531A1 (fr) * | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression |
-
2003
- 2003-02-27 EP EP03004184A patent/EP1452179A1/fr not_active Withdrawn
-
2004
- 2004-02-26 PE PE2004000199A patent/PE20050290A1/es not_active Application Discontinuation
- 2004-02-27 BR BRPI0408047-5A patent/BRPI0408047A/pt not_active IP Right Cessation
- 2004-02-27 SI SI200430815T patent/SI1603565T1/sl unknown
- 2004-02-27 JP JP2006501966A patent/JP2006519204A/ja active Pending
- 2004-02-27 KR KR1020057014683A patent/KR20050104367A/ko not_active Application Discontinuation
- 2004-02-27 AR ARP040100620A patent/AR043419A1/es not_active Application Discontinuation
- 2004-02-27 EP EP07009204A patent/EP1834643A3/fr not_active Withdrawn
- 2004-02-27 MX MXPA05009007A patent/MXPA05009007A/es active IP Right Grant
- 2004-02-27 UA UAA200507796A patent/UA82217C2/uk unknown
- 2004-02-27 ZA ZA200506820A patent/ZA200506820B/en unknown
- 2004-02-27 PL PL377814A patent/PL377814A1/pl not_active Application Discontinuation
- 2004-02-27 DE DE602004015260T patent/DE602004015260D1/de not_active Expired - Lifetime
- 2004-02-27 WO PCT/EP2004/001960 patent/WO2004075896A1/fr active IP Right Grant
- 2004-02-27 EA EA200501108A patent/EA008828B1/ru not_active IP Right Cessation
- 2004-02-27 ME MEP-322/08A patent/MEP32208A/xx unknown
- 2004-02-27 DK DK04715295T patent/DK1603565T3/da active
- 2004-02-27 CA CA002517321A patent/CA2517321A1/fr not_active Abandoned
- 2004-02-27 PT PT04715295T patent/PT1603565E/pt unknown
- 2004-02-27 CN CNB2004800053713A patent/CN100370986C/zh not_active Expired - Fee Related
- 2004-02-27 ES ES04715295T patent/ES2309503T3/es not_active Expired - Lifetime
- 2004-02-27 AU AU2004216472A patent/AU2004216472B2/en not_active Ceased
- 2004-02-27 CN CNA2007101120284A patent/CN101244063A/zh active Pending
- 2004-02-27 RS YUP-2005/0615A patent/RS20050615A/sr unknown
- 2004-02-27 AT AT04715295T patent/ATE401887T1/de not_active IP Right Cessation
- 2004-02-27 US US10/546,619 patent/US20070020190A1/en not_active Abandoned
- 2004-02-27 EP EP04715295A patent/EP1603565B1/fr not_active Expired - Lifetime
- 2004-02-27 NZ NZ541997A patent/NZ541997A/en unknown
- 2004-05-19 SA SA04250122A patent/SA04250122B1/ar unknown
-
2005
- 2005-07-29 TN TNP2005000186A patent/TNSN05186A1/en unknown
- 2005-08-23 HR HR20050726A patent/HRP20050726A2/xx not_active Application Discontinuation
- 2005-08-25 NO NO20053959A patent/NO20053959L/no not_active Application Discontinuation
- 2005-09-06 MA MA28483A patent/MA27630A1/fr unknown
-
2006
- 2006-06-21 HK HK06107053A patent/HK1087009A1/xx not_active IP Right Cessation
-
2008
- 2008-09-19 CY CY20081101023T patent/CY1108360T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA27630A1 (fr) | Medicament comportant un agoniste beta 2 de longue duree et tres puissant en combinaison avec d'autres ingredients actifs | |
Maina et al. | Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study | |
BRPI0013478B8 (pt) | medicamento compreendendo inibidor pde e uso de roflumilast | |
Settle et al. | Safety profile of sustained-release bupropion in depression: results of three clinical trials | |
MA41496B1 (fr) | Compositions pharmaceutiques comprenant n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
TWI535441B (zh) | 用以避免或治療乾眼症之含瑞巴派特或其前藥之口服藥物組成 | |
MXPA05004778A (es) | Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas. | |
BR0008699A (pt) | Combinações de formoterol e furoato demometasona para asma | |
MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
MA30779B1 (fr) | Comprimes pediatriques de capecitabine | |
JP2006104186A (ja) | 感冒用医薬組成物 | |
KR19990082367A (ko) | 치료 방법 및 약제학적 조성물 | |
PL404315A1 (pl) | Lek i kompozycja farmaceutyczna zawierajaca 5-hydroksy-7-chloro-1[2-metylo-4(2-metylobenzoiloamino)benzoilo]-2,3,4,5-tetrahydro-1H-benzoazepine do leczenia ciezkiej niewydolnosci serca oraz zastosowanie tego zwiazku do wytwarzania leku | |
MA27539A1 (fr) | Nouvelle combinaison synergique contenant du roflumilast et du formoterol | |
BR0214497A (pt) | Composição farmacêutica que compreende um agonista do receptor 5ht1 | |
CO5540290A2 (es) | Composicion que comprende un inhibidor de pde-4 y antagonista del receptor-hi y su uso en la manufactura de un medicamento para el tratamiento de enfermedades respiratorias | |
WO2005044186A3 (fr) | Formulations pharmaceutiques destinees a etre inhalees utilisant des agents dessechants et methodes d'administration desdites formulations pharmaceutiques | |
CR20210043A (es) | Forma de dosificación farmacèutica administrable por vía oral con liberación modificada | |
JPH05509300A (ja) | 上部気道における粘液分泌促進剤としてフェニルプロパノールアミンの使用 | |
SE9903995D0 (sv) | New combination | |
BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
MA27538A1 (fr) | Combinaison synergique comprenant du roflumilast et du (r,r)-formoterol | |
HUP0301408A2 (hu) | Szulodexid alkalmazása diabetikus vesebetegség kezelésére szolgáló orális gyógyszerkészítmény előállítására | |
DE60008590D1 (de) | Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern | |
HUP0202753A2 (hu) | A loteprednol és B2 adrenoreceptor agonisták új kombinációját tartalmazó gyógyszerkészítmények és alkalmazásuk |